{"id":295322,"date":"2023-04-05T00:00:00","date_gmt":"2023-04-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrop0007-2023-biopharma-glaucoma-current-treatment-current-treatment-physician-insights-glaucoma\/"},"modified":"2026-04-14T10:18:12","modified_gmt":"2026-04-14T10:18:12","slug":"cutrop0007-2023-biopharma-glaucoma-current-treatment-current-treatment-physician-insights-glaucoma-eu5","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrop0007-2023-biopharma-glaucoma-current-treatment-current-treatment-physician-insights-glaucoma-eu5\/","title":{"rendered":"Glaucoma &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Glaucoma (EU5)"},"content":{"rendered":"<p>Glaucoma is a progressive disease of the optic nerve caused by high intraocular pressure (<abbr title=\"intraocular pressure\">IOP<\/abbr>); it is one of the leading causes of vision loss in Europe. Treatment of glaucoma aims to lower and stabilize <abbr title=\"intraocular pressure\">IOP<\/abbr>. Pharmacotherapy is widely used, although nonpharmacological interventions continue to gain traction in the treatment of the major subtype of the disease\u2014primary open-angle glaucoma (<abbr title=\"open-angle glaucoma\">OAG<\/abbr>). Although the European glaucoma therapy market is crowded and highly genericized, branded therapies play an important role in later lines of treatment. The <abbr title=\"European Medicines Agency\">EMA<\/abbr>-approved therapies Rhokiinsa and Roclanda could further expand the treatment armamentarium for <abbr title=\"open-angle glaucoma\">OAG<\/abbr> if they become available in European markets. Nonpharmacological approaches to treating <abbr title=\"open-angle glaucoma\">OAG<\/abbr> include incisional glaucoma surgery, selective laser trabeculoplasty (<abbr title=\"selective laser trabeculoplasty\">SLT<\/abbr>), and devices for micro \/ minimally invasive glaucoma surgery (<abbr title=\"micro \/ minimally invasive glaucoma surgery\">MIGS<\/abbr>).<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How do treatment approaches differ between mild \/ moderate <abbr title=\"open-angle glaucoma\">OAG<\/abbr> and severe disease?<\/li>\n<li>Which pharmaceutical agents are most often prescribed for <abbr title=\"open-angle glaucoma\">OAG<\/abbr>?<\/li>\n<li>How successful are branded therapies such as Simbrinza and Diamox relative to generically available agents?<\/li>\n<li>Do ophthalmologists expect the <abbr title=\"European Medicines Agency\">EMA<\/abbr>-approved therapies Rhokiinsa and Roclanda to play a role in the treatment of glaucoma in the future?<\/li>\n<li>Which <abbr title=\"micro \/ minimally invasive glaucoma surgery\">MIGS<\/abbr> devices garner the greatest share among primary <abbr title=\"open-angle glaucoma\">OAG<\/abbr> patients?<\/li>\n<li>Have data from the <abbr title=\"Laser in Glaucoma and Ocular Hypertension\">LiGHT<\/abbr> trial on the use of <abbr title=\"selective laser trabeculoplasty\">SLT<\/abbr> in early lines of therapy influenced ophthalmologists\u2019 use of this approach?<\/li>\n<li>How do ophthalmologists envision their treatment of primary <abbr title=\"open-angle glaucoma\">OAG<\/abbr> evolving over the next three years?<\/li>\n<\/ul>\n<p><b>Product description<\/b><\/p>\n<p><em>Current Treatment: Physician Insights <\/em>provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n<p><strong>Markets covered:<\/strong><strong> <\/strong> <strong> <\/strong><abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>.<\/p>\n<p><strong>Primary research:<\/strong><strong> <\/strong> Survey of 253 <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr> ophthalmologists.<\/p>\n<p><strong>Key drugs covered: <\/strong>Simbrinza, Diamox, Betoptic, Iopidine, latanoprost, brimonidine, timolol, brinzolamide, Rhokiinsa, and Roclanda.<!--{C}%3C!%2D%2DEndFragment%20%2D%2D%3E--><\/p>\n<p><strong>Key companies: <\/strong>Alcon, Santen, Novartis, AbbVie, Pfizer, and Merck &#038; Co.<\/p>\n<p><strong>Key insights provided<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Factors influencing disease management and treatment decisions.<\/li>\n<li>Drivers of and constraints on treatment selection.<\/li>\n<li>Physician-reported treatment practices and brand-level patient shares.<\/li>\n<li>Rationale for changes in treatment approach.<\/li>\n<li>Physician insight on persistency and compliance.<\/li>\n<li>Physician-reported recent \/ anticipated changes in brand usage over the next three years.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-295322","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-glaucoma","biopharma-therapy-areas-ophthalmology","biopharma-product-current-treatment","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295322","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295322\/revisions"}],"predecessor-version":[{"id":576112,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295322\/revisions\/576112"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295322"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}